CLINICAL TRIAL

SAR408701 for Cancer

Locally Advanced
Metastatic
Waitlist Available · 18+ · All Sexes · Madrid, Spain

This study is evaluating whether a drug called SAR408701 can be given to patients with cancer.

See full description

About the trial for Cancer

Eligible Conditions
Neoplasms · Neoplasms, Malignant

Treatment Groups

This trial involves 9 different treatments. SAR408701 is the primary treatment being studied. Participants will be divided into 9 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Experimental Group 1
SAR408701
DRUG
Experimental Group 2
SAR408701
DRUG
Experimental Group 3
SAR408701
DRUG
Show More

Eligibility

This trial is for patients born any sex aged 18 and older. There are 7 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
For participants in the Dose Escalation Cohorts (Main Escalation and Loading Dose Cohorts at every 2 week cycle and Dose Escalation every 3 week cycle): patients with tumors expressing or likely to be expressing CEACAM5 which includes colorectal cancer (CRC), non-squamous non-small cell lung cancer (NSCLC), gastric adenocarcinoma, squamous cell carcinoma of the cervix, pancreas adenocarcinoma, bladder transitional cell carcinoma, cholangiocarcinoma, epithelial ovarian cancer and endometrial adenocarcinoma are favored, or if carcinoembryonic antigen (CEA) plasma levels >5 ng/mL.
At least one lesion amenable to biopsy (Expansion cohort - CRC and gastric cancer only). Patient must consent to a baseline biopsy for retrospective confirmation of tumor CEACAM5 expression, except if NSCLC or SCLC without lesion amenable to biopsy.
Signed informed consent.
Locally advanced or metastatic solid malignant tumor disease for which no standard alternative therapy is available.
Availability of archived tumor tissue for carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 or CEA) testing.
For participants to the Expansion Phase cohorts: patients with CRC or with CEACAM5 positive non-squamous NSCLC, small cell lung cancer (SCLC) or gastric carcinoma (including esophago-gastric junction adenocarcinoma of the Siewert types II and III).
At least one measurable lesion by RECIST v1.1 in the Expansion Phase only.
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 4 years
Screening: ~3 weeks
Treatment: Varies
Reporting: Up to 4 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 4 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether SAR408701 will improve 3 primary outcomes and 11 secondary outcomes in patients with Cancer. Measurement will happen over the course of 3 weeks.

Number of dose limiting adverse events (every 3 week cycle)
3 WEEKS
3 WEEKS
Number of dose limiting adverse events (every 2 week cycle)
4 WEEKS
4 WEEKS
Area under the plasma concentration versus time curve between 0 and 14 days (AUC0-14day) for Q2W or between 0 and 21 days (AUC-21 day) for Q3W
2 MONTHS
2 MONTHS
Accumulation ratio (Rac) on AUC0-14day and Cmax
2 MONTHS
2 MONTHS
Mean systemic clearance (CL)
2 MONTHS
2 MONTHS
Maximum concentration (Cmax)
2 MONTHS
2 MONTHS
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of cancer?

The signs depend on the type of cancer. Most of the signs and symptoms of cancer are not specific. Some of the signs of cancer can be similar to common health conditions. These signs and symptoms are not unique to cancer. Instead, they are present with many other disorders\n\nMost of the complaints are nonspecific when it comes to cancer. Patients present with symptoms of a specific disease, such as a lump in the breast or a lump found in the groin. Symptoms can vary depending on the form of cancer that is being diagnosed. Symptoms of cancer may also vary based on the prognosis that the patient has.

Anonymous Patient Answer

How many people get cancer a year in the United States?

around 70,000 newly diagnosed cancer cases are diagnosed every year in the United States. This makes up 12.1% of newly diagnosed cancer cases. There are significant variation in the incidence rates of cancer from one state to another. This indicates the need for accurate and objective data on cancer rates in US states to allow for efficient allocation of healthcare resources. However, this should not be taken as a means of estimating the incidence rates of cancer. The rate at which cancer cases are diagnosed should be considered when assessing the effectiveness of cancer prevention programs.

Anonymous Patient Answer

What causes cancer?

There are a variety of reasons for cancer, ranging from genetics to lifestyle choices. For some cancers, there is a hereditary component. Cancers can be spread through infection. The development of cancer is often linked with the production of chemical toxins in the body.

Anonymous Patient Answer

What are common treatments for cancer?

Chemotherapy used more frequently and was the treatment applied in a larger proportion of cancer cases with the exception of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer). The most common treatment for cancer is surgery, either as curative intent or to provide palliative care. This chapter describes the treatments for cancers of the breast, lung, colon, rectum, pancreas, kidney, brain, throat, prostate, and ovarian.

Anonymous Patient Answer

Can cancer be cured?

For some cancers there exists considerable support for a cure. However, the problem of the definition of cure remains. In the case of some cancers, a cure is a concept which has real meaning for patients. Most scientists agree that, to speak of cure implies that the cure has been found, but these results should be matched to the extent that an effective control in a well-trained health-care system can be guaranteed. It is hard to prove a cure of cancer and it is difficult when no cure has yet been found. With respect to prostate cancer these results are discussed on the basis of the available information.

Anonymous Patient Answer

What is cancer?

Cancer was the third-leading cause of death among Canadians aged 15 and older, and the leading cause of death among persons 40 to 74 years old. The majority of cancer deaths were due to lung, breast and colon cancers. The majority of new cancers occurred in the colon, skin, pancreas and bladder in females and in the lungs, prostate, stomach and stomach in males. Most cancers occurred in Caucasians, but more blacks and Asians were diagnosed with lung cancer. Many people who are diagnosed with cancers are not adequately screened for cancer, and this has the potential to increase survival rates, although evidence on benefits of screening has been limited since the 1960s.

Anonymous Patient Answer

Does cancer run in families?

People should be cautious before taking any medical advice based on familial clustering, particularly in cases where cancer is an infrequent cause of death and of this cases the likelihood of an alternative diagnosis is high. There is also urgent need to build a national database of hereditary cancer susceptibility genes where possible by collecting the personal and family histories of cancer victims. This would greatly simplify the search for known genes and it would enable scientists and clinicians to build and validate a risk score for hereditary cancers as a predictive tool for patients and their relatives. Such a score would make it possible to identify the high risk patients and their relatives who need closer surveillance. This can be useful to detect other genetic defects in family members who may be at an increased risk and therefore potentially treatable.

Anonymous Patient Answer

What is sar408701?

Given the number of anticancer agents being developed and evaluated, many drugs would still be missing. SarA408701 was a potent and selective inhibitor of Src; the Src protein is essential for cellular signals and cellular behaviours such as proliferation and migration.

Anonymous Patient Answer

How does sar408701 work?

Findings from a recent study suggest that sar408701 has a potent direct cytotoxic effect against the SGC7901 cells. Moreover, the cell death induced by sar408701 might trigger SGC7901 cell apoptosis through the decrease of Bcl-2 expression and the enhancement of Bax expression. Taken together, these findings suggest that sar408701 might be a potential chemotherapeutic agent for SGC7901 cells and further research is warranted.

Anonymous Patient Answer

Have there been other clinical trials involving sar408701?

Sar408701 produced a significant antitumor response in patients with advanced solid tumors. Because sar408701 had the same structure as the natural compound saralasin, it will help to identify which sites in Sar1 should be modified to achieve a more active drug.

Anonymous Patient Answer

What are the common side effects of sar408701?

Sar408701 has been evaluated for the treatment of a variety of malignant diseases for the past 15 years, including [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), breast cancer, cervical cancer, and hepato-pancreatic cancer. There are both antitumor and cytotoxic activities of sar408701 as well as very few and transient toxicity events that can include transient loss of appetite, fatigue, insomnia, and mild or moderate nausea and vomiting. Overall, sar408701 is well tolerated, including in patients with a history of allergy or hypersensitivity to sar408701, and sar408701 has not been discontinued in the pediatric population.

Anonymous Patient Answer

What is the average age someone gets cancer?

The average age of diagnosis of any cancer of male and female cancer patients was 59 and 57 years respectively. The prevalence of breast and cervical cancer for male and female cancer patients was 5.4 and 5.0, respectively. Ovarian and prostate cancers were more common in female patients than males. The average survival time of male carcinoma patients was 6.9 years and for the female patients was 7.1 years. The age group of 50-69 years was most affected by breast and cervical cancer. In other cancer types, the age groups 10-20 and 30-39 years showed the poorest prognosis.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cancer by sharing your contact details with the study coordinator.